Utah Medical Products Inc. reported financial results for the third quarter and first nine months of 2025. For the third quarter, revenues declined by 2% compared to the same period in 2024, and gross profit decreased by 3%. Operating income was down 22%. Income before tax fell by 21%, and net income declined by 26%. For the first nine months of 2025, revenues dropped by 7% compared to the previous year period, with gross profit down by 11%. Operating income decreased by 16%. Income before tax declined by 17%, and net income was down 21%. As of September 30, 2025, stockholders' equity was $118.3 million, compared to $117.5 million at the end of the previous quarter and $117.4 million as of September 30, 2024. Total liabilities and stockholders' equity were $122.0 million at the end of the third quarter of 2025, compared to $120.8 million at the end of the previous quarter and $122.5 million a year earlier.